 2 Package leaflet: Information for the
 user
   Flucelvax Tetra
 - suspension for injection in pre
-filled syringe
 Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
  This medicine is 
subject to additional monitoring. This will allow quick identification of new 
safety information. You can help by reporting any side effects you may get. See the end of section 4 
for how to report side effects.
  Read all of this leaflet carefully before yo
u receive
 this medicine because it contains important 
information for you.
 - Keep this leaflet. You may need to read it again. 
 - If you have any further questions, ask your doctor,
 pharmacist or nurse.
 - If you get any side effects, talk to your doctor,
 pharmacist or nurse.
 This includes any possible 
side effects not listed in this leaflet
. See section 4.
   What is in this leaflet
  1. What 
Flucelvax Tetra 
is and what it is used for 
 2. What you need to know before you 
receive
 Flucelvax Tetra
  3. How 
Flucelvax Tetra 
is given
  4. Possible side effects 
 5. How to store 
Flucelvax Tetra 
  6. Contents of the pack and other information
   1. What 
Flucelvax Tetra
 is 
and what it is used for
  Flucelvax Tetra
 is a vaccine against flu (influenza).
 Flucelvax Tetra
 is prepared in cell cultures, and
, therefore, is egg
-free.
 When a person is given the vaccine, the immune system (the body™s natural defence system) will 
produce its own protection against the influenza virus. None of the ingredients in the vaccine can 
cause flu.
  Flucelvax Tetra
 is used to prevent flu in adults and children from 
2 years of age.
  The vaccine targets 
four
 strains of influenza virus following the recommendations by the World 
Health Organisation for the 
2020/202
1 season.
   2. What you need to know 
before you 
receive
 Flucelvax Tetra
  You should not receive
 Flucelvax Tetra
: If you are allergic to
:  the active ingredients or 
any of the other ingredients of this medicine (listed in section
 6)  beta
-propiolactone, 
cetyltrimethylammonium bromide, or polysorbate
 80, which are 
trace 
residues from the manufacturing process
.  Warnings and precautions 
 Talk to your doctor
, pharmacis
t or nurse before 
receiving
 Flucelvax Tetra
.  BEFORE receiving the vaccine
  Your 
doctor or 
nurse
 will make sure that appropriate medical treatment and supervision is readily 
available in case of a rare anaphylactic reaction (a very severe allergic reaction with symptoms 
  3 such as difficulty in breathing, dizziness, a weak and rapid pulse and skin 
rash) following the 
administration. This reaction may occur with 
Flucelvax Tetra
 as with all vaccines that are injected.
  You should tell your doctor if you have an acute illness associated with fever.
 Your doctor
 may 
decide to delay your vaccination until your fever is gone.
  You
 should tell your doctor if your immune system is impaired, or if you are undergoing treatment 
which affects the immune system, e.g. with medicine against cancer (chemotherapy) or 
corticost
eroid medicines (see 
section ﬁ
Other medicines
 and Flucelvax Tetra
ﬂ).
  You should tell your doctor if you have a bleeding problem or bruise easily.
  Fainting can occur following, or even before, any needle injection, therefore tell the doctor or 
nurse if you 
fainted with a previous injection.
  As with all vaccines, Flucelvax Tetra may not fully protect all persons who are vaccinated.
  Other medicines and 
Flucelvax Tetra
  Tell your doctor or 
nurse
 if you are using, have recently 
used or might use any other 
medicines
, including medicines obtained without a prescription or if you have recently received any other 
vaccine.
  Flucelvax Tetra
 may be given at the same time as other vaccines.
  Pregnancy 
and 
breast
-feeding
  Pregnancy:
 Tell your doctor if you are pregnant, think you may be pregnant or 
are 
plan
ning
 to 
have a baby
. Influenza vaccinations can be used at any stage of pregnancy
.   Breast
-feeding:
 Use of 
Flucelvax Tetra
 during breast
-feeding has not been studied.
 Flucelvax 
Tetra may be used 
during
 breast
-feeding.
  Driving and using machines
 Flucelvax Tetra
 has no or negligible effect on your ability to drive and use machines.
  Flucelvax Tetra
 contains
 sodium chloride and potassium chloride
 This vaccine contains less than 1
 mmol sodium (23
 mg) per dose, i.e. essentially ‚sodium free™.
 This vaccine contains potassium, less than 1
 mmol (39
 mg) per dose, i.e. essentially ‚potassium free™.
   3. How 
Flucelvax Tetra
 is given
  Flucelvax Tetra
 is given to you by your doctor or nurse
 as an injection into the muscle 
at 
the top of the 
upper arm (deltoid muscle).
  Adults 
and children 
from 
2 years
 of age
:  One dose of 0.5
 ml
   4. Possible side effects
  Like all medicines, 
this medicine 
can cause side effects, although not everybody gets 
them.
 The following side effects have been 
reported
 during clinical trials and 
during general use
:  Very serious side effects
 Tell your doctor immediately or go to the casualty department at your nearest hospital if you 
experience the following side effect
 Œ you may need urgent medical attention or hospitalisation:
    4 Ł difficulty in breathing, dizziness, a weak and rapid pulse and skin rash which are symptoms of an 
anaphylactic reaction (a very severe allergic reaction)
  Serious side effects
 Tell your doctor i
mmediately if you experience any of the following side effects 
Œ you may need 
medical attention:
  Ł Extensive swelling of injected limb
  Mild side effects
 Very common
 (may 
affect more than 1 in 10
 people
): Ł Injection site pain,
 bruising
, reddening
 and
 hardening or swelling at the site of the injection
 Ł Headache
 Ł Muscle pain
   Ł Tiredness
  Ł Loss of appetite
 Ł Irritability 
(only reported 
in 
children from 2 to < 6 years)
 Ł Sleepiness 
(only reported 
in 
children 
2 to <
 6 years)
 Hardening or swelling at the site of 
the injection, headache
, muscle pain
, and 
tiredness
 were common 
in the elderly.
 Bruising at the site of the injection was common in adults, eldery and children 9 to < 18 years
 Headache was common in 
the elderly
 Loss of appetite was common in 
adults, eldery
 and children 9 to < 18 years
  Common
 (may 
affect 
up to 
1 in 10
 people
): Ł Nausea, 
vomiting, 
diarrhoea 
 Ł Joint pain
 Ł Shivering
 Ł Change in eating habits
 (only reported 
in 
children from 2 to < 6 years)
 Ł Fever
 (> 38°C)
 Vomiting was uncommon in the elderly
. Fever 
was uncommon in adults and the elderly
  Not known
 (cannot be estimated from the available data):
 Ł Numbness and tingling sensation
 Ł Generalised skin reactions including itching, bumps on the skin or non
-specific rash
  Reporting of side effects
 If you get 
any 
side effects
, talk to your healthcare professional
. This includes any possible 
side effects 
not listed in this leaflet.
 You can also report side effects directly 
via 
the Yellow Card Scheme at: 
www.mhra.gov.uk/yellowcard
 or search for MHRA Yellow Card in the Google Play or Apple App 
Store.
  By reporting side effects
, you can help provide more information on the safety of this medicine.
   5. How to store 
Flucelvax Tetra
   Keep 
this 
vaccine
 out of 
the 
sight 
and reach 
of children.
  Store in a refrigerator (2 °C
 to 8 °C). Do not freeze.
 Keep the pre
-filled syringe in the outer carton in order to protect from light.
  Do not use 
this 
vaccine
 after the expiry date which is stated on the label 
and 
carton
 after 
EXP
. The 
expiry date refers to the last day of 
that 
month.
  Do not throw away any medicines via wastewater or household waste. Ask you pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.
    5  6. Contents of the pack and other information
  What 
Flucelvax Tetra
 contains 
  The active substances are
 influenza virus surface antigens (haemagglutinin and neuraminidase), 
inactivated, of the following strains
*:  A/Hawaii/70/2019 (H1N1)pdm
09-like strain (A/Nebraska/14/2019, wild type) 
15 micrograms HA**
 A/Hong Kong/45/2019 (H3N2)
-like strain (A/Delaware/39/2019, wild type) 
15 micrograms HA**
 B/Washington/02/2019
-like strain (B/Darwin/7/2019, wild type) 
15 micrograms HA**
 B/Phuket/3073/2013
-like strain (B/Singapore/INFTT
-16-0610/2016, wild type) 15
 micrograms HA**
  per
 0.5
 ml dose
 –––––––––––––––.
 * pro
pagated
 in Madin Darby Canine Kidney (MDCK) cells (this is the special cell culture in 
which the influenza virus is grown)
;  ** haemagglutinin
  This vaccine complies with the World Health Organisation (WHO) recommendation (northern 
hemisphere) and EU recommendation for the 
2020/202
1 season.
  The other ingredients are: 
sodium chloride, potassium chloride, magnesium chloride 
hexahydrate, 
disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections.
  What 
Flucelvax Tetra 
looks like and contents of the pack
  Flucelvax Tetra
 is a suspension for injection in a pre
-filled syringe (ready to use syringe). 
 Flucelvax Tetra
 is a clear to slightly opalescent suspension.
 A single syringe contains 0.5
 ml of suspension for injection.
 Flucelvax Tetra
 is available in packs containing 
1 pre
-filled syringe with 
or without 
needle
 or 
10 pre
-filled syringes 
with or 
witho
ut needles.
 Not all pack sizes may be marketed.
  Marketing Authorisation Holder 
 Seqirus Netherlands B.V.
 Paasheuvelweg 28
 1105BJ Amsterdam
 Netherlands
  Manufacturer
 Seqirus Vaccines Limited
 Gaskill Road, Speke
 L24 9GR Liverpool
 United Kingdom
  Seqirus 
Netherlands B.V.
 Paasheuvelweg 28
 1105BJ Amsterdam
 Netherlands
  For any 
information about this medicine, please contact the local representative of the Marketing 
Authorization Holder:
  Belgi
ë/Belgique/Belgien
 Seqirus Netherlands B.V.
Nederland
/Netherlands
 Lietuva
 Seqirus Netherlands B.V.
 Nyderlandai
   6 Tel: 
+31 (0) 20 204 6900
  
 Seqirus Netherlands B.V.
 
 
.: +31 (0) 20 204 6900
  eská republika
 Seqirus Netherlands B.V.
 Nizozemsko
 Tel: 
+31 (0) 20 204 6900
  Danmark
 Seqirus Netherlands B.V.
 Holland
 Tlf: 
+31 (0) 20 204 6900
  Deutschland
 Seqirus GmbH 
Marburg
 Tel: 
08003601010
  Eesti
 Seqirus Netherlands B.V.
 Holland
 Tel: 
+31 (0) 20 204 6900
  
 Seqirus Netherlands B.V.
 
 
: +31 (0) 20 204 6900
  Espa
ña Seqirus Spain, S.L., Barcelona
 Tel: 
937 817 884
  France
 Seqirus Netherlands 
B.V.
 Netherlands
 Tél: +31 (0) 20 204 6900
  Hrvatska
 Seqirus Netherlands B.V.
 Nizozemska
 Tel: 
+31 (0) 20 204 6900
  Ireland
 Seqirus UK Limited
 Maidenhead
 Tel: +44 1628 641 500
  Ísland
 Seqirus Netherlands B.V.
 Holland
 Sími: 
+31 (0) 20 204 6900
  Italia
 Seqirus S.r.l. 
Siena
 Tel: +39 
0577 096400
  
 Seqirus Netherlands B.V. 

 
: +31 (0) 20 204 6900
  Latvija
 Seqirus Netherlands B.V.
 
 Tel: 
+31 (0) 20 204 6900
  Luxembourg/Luxemburg
 Seqirus Netherlands B.V.
 Netherlands
 Tél/Tel: 
+31 (0) 20 204 6900
  Magyarorsz
ág Seqirus Netherlands B.V.
 Hollandia
 Tel.: 
+31 (0) 20 204 6900
  Malta
 Seqirus Netherlands B.V.
 In-Netherlands
 Tel: 
+31 (0) 20 204 6900
  Nederland
 Seqirus 
Netherlands B.V.
 Amsterdam
 Tel: 
+31 (0) 20 204 6900
  Norge
 Seqirus Netherlands B.V.
 Nederland
 Tlf: 
+31 (0) 20 204 6900
  Österreich
 Valneva Austria GmbH, Wien
 Tel: 
+43 1 20620 
  Polska
 Seqirus Netherlands B.V.
 Holandia
 Tel.: 
+31 (0) 20 204 6900
  Portugal
 Seqirus Netherlands B.V.
 Países Baixos
 Tel: 
+31 (0) 20 204 6900
  Rom
ânia Seqirus Netherlands B.V.
 Olanda
 Tel: 
+31 (0) 20 204 6900
  Slovenija
 Seqirus Netherlands B.V.
 Nizozemska
 Tel: 
+31 (0) 20 204 6900
  Slovensk
á republika
 Seqirus Netherlands B.V.
 Holandsko
 Tel: 
+31 (0) 20 204 6900
  Suomi/Finland
 Seqirus Netherlands B.V.
 Alankomaat
 Puh/Tel: 
+31 (0) 20 204 6900
  Sverige
 Seqirus Netherlands B.V.
 Nederländerna
 Tel: 
+31 (0) 20 204 6900
  United Kingdom
 Seqirus UK Limited
 Maidenhead
   7 Tel: 
+31 (0) 20 204 6900
  Tel: 
+44 1628 641 500
    This leaflet was last 
revised i
n 10/2020
.  Other sources of information
  Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu
.   ---------------------------------------------------------------------------------------------------------------------------
 The following information is intended for healthcare professionals only:
  Appropriate medical treatment and supervision should alway
s be readily available in case of a rare 
anaphylactic event following the administration of the vaccine.
  Shake before use. After shaking, the normal appearance of the vaccine is a clear to slightly opalescent 
suspension.
  The vaccine should be visually in
spected for particulate matter and discoloration prior to 
administration. In the event of any foreign particulate matter and/or variation of physical aspect being 
observed, do not administer the vaccine.
  